Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 14/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9839171 | 0.98 | WDR5 (0.71) | WDR5ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL989261 | 0.84 | WDR5 (1.00) | WDR5ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL4839735 | 0.81 | WDR5 (0.71) | WDR5ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL4839937 | 0.79 | WDR5 (0.90) | WDR5ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL9199162 | 0.78 | WDR5 (1.00) | WDR5ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL9293256 | 0.78 | WDR5 (0.66) | WDR5ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL9698908 | 0.77 | LMNA (0.70) | WDR5ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL5308466 | 0.77 | ALDH1A1 (0.70) | WDR5ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL5778043 | 0.77 | LMNA (0.70) | WDR5ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL15933687 | 0.76 | PDCD1 (0.53) | WDR5ALDH1A1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1032011-A | Pyrrolo-imidazoles and imidazopyridine and application thereof | SMITHKLINE BECKMAN CORP (US) | 1989-03-29 | — | — | CN | claimed |
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-02-01 | — | — | US | disclosed |
| US-9790203-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2922842-B1 | INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC (US) | 2017-06-14 | — | — | EP | disclosed |
| CN-104995183-A | Novel phosphodiesterase type 10A inhibitor compounds | ABBVIE INC | 2015-10-21 | — | — | CN | disclosed |
| EP-2922842-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079995-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
| US-5145858-A | Antiinflammatory | SMITHKLINE BEECHAM CORP. (US) | 1992-09-08 | — | — | US | disclosed |
| US-5002941-A | Antiarthritic agents, arachidonic acid metabolism | SMITHKLINE BEECHAM CORPORATION (US) | 1991-03-26 | — | — | US | disclosed |
| WO-1990003789-A1 | PYRROLO[1,2-a]IMIDAZOLE AND IMIDAZO[1,2-a]PYRIDINE DERIVATIVES AND THEIR USE AS 5-LYPOXYGENASE PATHWAY INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-04-19 | — | — | WO | disclosed |
| EP-0364204-A1 | Pyrrolo[1,2-a]imidazole and imidazo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1990-04-18 | — | — | EP | disclosed |
| CN-1032011-A | Pyrrolo-imidazoles and imidazopyridine and application thereof | SMITHKLINE BECKMAN CORP (US) | 1989-03-29 | — | — | CN | disclosed |
| EP-0306300-A2 | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | WDR5 4542/4885ALDH1A1 272/4885LMNA 1231/4885 |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | WDR5 4548/4885ALDH1A1 273/4885LMNA 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.